公开(公告)号：US20240350439A1

公开(公告)日：2024-10-24

申请号：US18759093

申请日：2024-06-28

Applicant: METIMEDI PHARMACEUTICALS CO., LTD.

Inventor： Chong Hwan CHANG ,  Keun-Yeong JEONG

IPC: A61K31/19 ,  A23L33/10 ,  A23L33/165 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61K33/06 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  A61K47/40 ,  A61K47/44 ,  A61P35/00

CPC classification number: A61K31/19 ,  A23L33/10 ,  A23L33/165 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/08 ,  A61K9/10 ,  A61K9/2054 ,  A61K9/2081 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/5026 ,  A61K9/5042 ,  A61K33/06 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  A61K47/40 ,  A61K47/44 ,  A61P35/00 ,  A23V2002/00 ,  A23V2200/308 ,  A23V2250/042 ,  A23V2250/1578

Abstract: The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.

公开(公告)号：US20240325361A1

公开(公告)日：2024-10-03

申请号：US18500471

申请日：2023-11-02

Applicant: Akebia Therapeutics, Inc.

Inventor： Alexander Smith ,  Gurudatt Ajay Chandorkar ,  Ene Ikpong Ette ,  Bradley John Maroni ,  Charlotte Suzanne Hartman ,  Ramin Farzaneh-Far ,  Jula Kern Inrig

IPC: A61K31/4418 ,  A61K9/20 ,  A61K9/28 ,  A61K31/16 ,  C07D213/81

CPC classification number: A61K31/4418 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2866 ,  A61K31/16 ,  C07D213/81

Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

公开(公告)号：US20240307314A1

公开(公告)日：2024-09-19

申请号：US18569780

申请日：2023-05-11

Applicant: KYOWA Pharmaceutical Industry Co., Ltd.

Inventor： Hiroki SHINGAKI ,  Shota ASAI ,  Fumiyasu TANIGUCHI ,  Junya YAMASHITA

IPC: A61K9/28 ,  A61K9/20 ,  A61K31/167

CPC classification number: A61K9/2866 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/286 ,  A61K9/2893 ,  A61K31/167

Abstract: By coating an oral solid preparation with a gel film containing a polymer gelable on contact with water, a carbonate, and an acidic substance, obtained oral solid composition is easy to swallow, and elution of active ingredients is suppressed, while the composition can disintegrate in the oral cavity. When an oral solid composition comprising a gel film is hermetically packed or is tightly packed together with a desiccant, discoloration during storage can be suppressed. In a gel film, by setting the concentration of glycerol at 2% by mass or less relative to the total amount of the gel film, mold is prevented from growing. In the case where a coating liquid in which a polymer gelable on contact with water is dispersed is used to form a gel film, the gel film can be formed for a short period of time, even when the coating liquid contains a large amount of the polymer. A gel fil containing titanium oxide at 20% by mass or less can be identifiably marked by ultraviolet laser irradiation.

公开(公告)号：US20240293420A1

公开(公告)日：2024-09-05

申请号：US18568415

申请日：2022-06-10

Applicant: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.

Inventor： Huayun Hong ,  Jian Hang ,  Jun Lou ,  Li Liu ,  Wei Wu ,  Yongkai Chen ,  Yihan Zhang ,  Chaodong Wang

IPC: A61K31/5377 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K31/5377 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2853 ,  A61K9/2866

Abstract: Disclosed in the present invention are a pharmaceutical composition, a preparation, and a preparation method therefor and the use thereof. The pharmaceutical composition contains an active ingredient and a pharmaceutically acceptable excipient. The active ingredient contains a compound represented by formula A. The compound represented by formula A is selected from one, two or more of the crystal form I, the crystal form III and the crystal form V. The excipient is selected-from or comprises, but is not limited to, one, two or more of the following excipients: a diluent, a disintegrant, an adhesive, a glidant and a lubricant. The pharmaceutical composition and the preparation of the present invention have a good safety and/or stability, and a high P2X3 antagonistic activity, and have less effect on the taste.

公开(公告)号：US12077549B2

公开(公告)日：2024-09-03

申请号：US17378852

申请日：2021-07-19

Applicant: Galera Labs, LLC

Inventor： Jeffery L. Keene ,  Otto F. Schall ,  Dennis P. Riley

IPC: C07F13/00 ,  A61K9/00 ,  A61K9/28 ,  A61K9/48 ,  A61K31/28 ,  A61K31/555 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44 ,  A61P1/00 ,  A61P17/00

CPC classification number: C07F13/005 ,  A61K9/0019 ,  A61K9/2866 ,  A61K9/4816 ,  A61K31/28 ,  A61K31/555 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44 ,  A61P1/00 ,  A61P17/00

Abstract: Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X1.






each of the two axial ligands has the formula —OC(═O)X1 wherein each X1 is independently substituted or unsubstituted phenyl or —C(—X2)(—X3)(—X4);
each X2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl;
each X3 is independently hydrogen, hydroxyl, alkyl, amino, —X5C(═O)R13 where X5 is NH or O, and R13 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or —OR14, where R14 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or together with X4 is (═O); and
each X4 is independently hydrogen or together with X3 is (═O).

公开(公告)号：US20240277621A1

公开(公告)日：2024-08-22

申请号：US18441344

申请日：2024-02-14

Applicant: Shin-Etsu Chemical Co., Ltd.

Inventor： Shun FURUYA ,  Yasuyuki HIRAMA

IPC: A61K9/28 ,  A61K47/02 ,  A61K47/18 ,  A61K47/38

CPC classification number: A61K9/2866 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/2893 ,  A61K47/02 ,  A61K47/18 ,  A61K47/38

Abstract: Provided is an aqueous composition that is acid-resistant, does not cause blockage of spray nozzle even without a cooling equipment, and can be suitably used in an enteric coating preparation in a simple and convenient manner. The aqueous composition includes hydroxypropyl methyl cellulose acetate succinate having an acetyl group substitution degree from 0.10 to 2.50 and a succinyl group substitution degree from 0.05 to 2.50 per number of anhydroglucose unit; a neutralizer; and water. The degree of neutralization of the hydroxypropyl methyl cellulose acetate succinate by the neutralizer is from 130 to 260 mol %.

公开(公告)号：US12059426B2

公开(公告)日：2024-08-13

申请号：US18221784

申请日：2023-07-13

Applicant: ARMGO Pharma, Inc.

Inventor： Eugene E. Marcantonio ,  Mette Uhre Anby ,  Jérôme Binet

IPC: A61K31/554 ,  A61K9/28 ,  A61P21/00

CPC classification number: A61K31/554 ,  A61K9/2866 ,  A61K9/2886 ,  A61P21/00

Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.

公开(公告)号：US12059409B1

公开(公告)日：2024-08-13

申请号：US18613270

申请日：2024-03-22

Applicant: ASTELLAS PHARMA INC.

Inventor： Yuuki Takaishi ,  Yutaka Takahashi ,  Takashi Nishizato ,  Daisuke Murayama ,  Emiko Murayama ,  Soichiro Nakamura ,  Kazuhiro Sako

IPC: A61K31/426 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K31/426 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/2853 ,  A61K9/2866

Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl) amino]ethyl] acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.

公开(公告)号：US20240197661A1

公开(公告)日：2024-06-20

申请号：US18492882

申请日：2023-10-24

Applicant: Arbor Pharmaceuticals, LLC

Inventor： Peter A. VIRSIK ,  Sami KARABORNI ,  Laura Elizabeth BAUER ,  Chen MAO ,  Ching Wah CHONG

IPC: A61K31/197 ,  A61K9/20 ,  A61K9/28 ,  A61P17/06

CPC classification number: A61K31/197 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2866 ,  A61P17/06

Abstract: Methods of treating psoriasis with sustained release compression coated tablet dosage forms comprising certain MHF prodrugs are provided.

公开(公告)号：US20240189408A1

公开(公告)日：2024-06-13

申请号：US18486678

申请日：2023-10-13

Applicant: Arkea Bio Corp.

Inventor： Colin South ,  Matthew Dunn ,  Lauren Fitch ,  Joseph Koos ,  Laura Holland ,  Brigid Arciero ,  James Spoonamore ,  Caitlin Allen ,  Alexander Hsu ,  Sara Tabandeh ,  Frederick Richard Kearney ,  Christopher Warren Rivest

IPC: A61K39/02 ,  A61K9/20 ,  A61K9/24 ,  A61K9/28 ,  A61K9/50 ,  A61K31/7105 ,  A61P31/04

CPC classification number: A61K39/0208 ,  A61K9/2009 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2063 ,  A61K9/209 ,  A61K9/2866 ,  A61K9/5052 ,  A61K31/7105 ,  A61P31/04 ,  A61K2039/53

Abstract: The present invention is related to compositions and methods that reduce methane production in ruminant populations.